Literature DB >> 18723368

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

John M Fitzpatrick1, John Anderson, Cora N Sternberg, Neil Fleshner, Karim Fizazi, Xavier Rébillard, Luigi Dogliotti, Giario Conti, Ingela Turesson, Nicholas James, Axel Heidenreich, Eduardo Solsona, Vicente Guillem, Daniel Herchenhorn, Judd Moul, Jeroen van Moorselaar, Lance J E Coetzee, Andrew Wilson, Aristotelis Bamias, Ronald De Wit, Michael Chrisofos.   

Abstract

A multidisciplinary panel of 20 international experts, including urologists, radiation oncologists, and medical oncologists, convened during the Advanced Prostate Cancer Multidisciplinary Team meeting in Rome, Italy, in January 2007, to discuss the multidisciplinary team approach and current patterns of care for patients with hormone-refractory prostate cancer (HRPC). During the meeting, the experts discussed several definitions currently used in prostate cancer management, including those for senior adult patients. In addition, the panel reviewed a series of patient case studies in order to provide feedback on current treatment practices and to identify possible strategies for best practice. It was stressed that treatment decisions for senior adult patients should not be based solely on patient age. Additionally, although historically treatment decisions for advanced prostate cancer have focused on palliative care, given the survival benefit associated with docetaxel-based chemotherapy across patient subgroups, more men are likely to be offered chemotherapy for advanced-stage disease in the future.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723368     DOI: 10.1016/j.critrevonc.2008.07.019

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  7 in total

1.  Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells.

Authors:  Konstantin V Golovine; Peter B Makhov; Ervin Teper; Alexander Kutikov; Daniel Canter; Robert G Uzzo; Vladimir M Kolenko
Journal:  Prostate       Date:  2012-05-16       Impact factor: 4.104

2.  Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors.

Authors:  Bishoy A Gayed; Katherine J O'Malley; Jan Pilch; Zhou Wang
Journal:  Clin Transl Sci       Date:  2012-02-23       Impact factor: 4.689

Review 3.  Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.

Authors:  Oliver Sartor; Ross M Michels; Christophe Massard; Johann Sebastian de Bono
Journal:  Oncologist       Date:  2011-11-02

Review 4.  Carcinomas of an unknown primary origin--diagnosis and treatment.

Authors:  Christophe Massard; Yohann Loriot; Karim Fizazi
Journal:  Nat Rev Clin Oncol       Date:  2011-11-01       Impact factor: 66.675

5.  Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer.

Authors:  Lara Bellardita; Simona Donegani; Andrea L Spatuzzi; Riccardo Valdagni
Journal:  J Oncol Pract       Date:  2011-01       Impact factor: 3.840

6.  Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.

Authors:  Nicole M Engel-Nitz; Berhanu Alemayehu; David Parry; Faith Nathan
Journal:  Cancer Manag Res       Date:  2011-07-04       Impact factor: 3.989

7.  ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3.

Authors:  Lijie Zhou; Zhengshuai Song; Junyi Hu; Lilong Liu; Yaxin Hou; Xiaoping Zhang; Xiong Yang; Ke Chen
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.